Gene Therapy Cure For Blindness Gets $850K Price TagThe one-time injection will cost patients $425,000 per eye and reverses the disease called retinal dystrophy.
RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent ApplicationRetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12,299,574), which broadly covers methods of restoring visual responses with a variety of optogenetic compounds.
HR Notices From October 4The latest staffing, leadership and boardroom news from Michigan's technology-focused companies, institutions and groups
RetroSense Therapeutics Completes pre-IND Meeting for RST-001RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research division of the FDA that took place on May 22 regarding RetroSense’s lead product candidate, RST-001 for vision restoration in retinal degenerative conditions.
HR Notices From April 19The latest staffing, leadership and boardroom news from Michigan's technology-focused companies, institutions and groups.
Wayne State Gets Licenses For Breakthrough Approaches to Vision RestorationRetroSense Therapeutics LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.
UM: First Clinical Trial of Gene Therapy Shows Promise In Easing PainIn the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief.
Study: 'Meaningful improvements' Using Gene Therapy in Parkinson's DiseaseA first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery
Kalamazoo's ProNAi Starts Trial Of Cancer Drug